Deep vein thrombosis after insertion of a central venous catheter: a case report.

Pan Afr Med J

Nephrology Division, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Dr. Soetomo Hospital, Surabaya, Indonesia.

Published: August 2022

A male patient aged 50 years, presented with a swelling in the right leg which had occurred five days before hospital admission. This was associated with pain in the swollen leg. The patient had a history of femoral double lumen catheter (DLC) insertion for hemodialysis. On physical examination, Wong Baker's scale was 3, Wells' score was 3, and the patient had edematous, red, and warm right lower extremity. Laboratory results showed anemia (Hb 11.4 g/dl), leukocytosis (27.99 x 10/ul), increased blood urea nitrogen (BUN) (60 mg/dl), increased serum creatinine (9.93 mg/dl), hyperkalemia (6 mmol/l), urine leukocytes +3; 15-20/hpf. Lower extremity ultrasound revealed diffuse deep vein thrombosis (DVT). After the diagnosis of DVT, the patient was treated with fondaparinux injection and warfarin as an anticoagulant for six days. Our results show that treatment was effective in reducing swelling and pain in the right leg, that disappeared after a three months´ treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288144PMC
http://dx.doi.org/10.11604/pamj.2022.42.25.34452DOI Listing

Publication Analysis

Top Keywords

deep vein
8
vein thrombosis
8
lower extremity
8
thrombosis insertion
4
insertion central
4
central venous
4
venous catheter
4
catheter case
4
case report
4
report male
4

Similar Publications

Background: This single center-based prospective cohort study was conducted, on 157 patients over 60 years old patients requiring major orthopedic surgery, from June 2019 to June 2021. Frailty was assessed using the Edmonton Frailty Scale pre-operatively. Post-operative complications, ambulatory status, readmission rates, and mortality were monitored up to three months post-surgery, and statistical analysis was performed.

View Article and Find Full Text PDF

We investigated the safety and efficacy of rivaroxaban as routine thromboprophylaxis after endovenous thermal ablation (EVTA). Adhering to the PRISMA 2020 guidelines, we conducted a systematic review for studies published up to April 2024. Primary endpoints included endovenous heat-induced thrombosis (EHIT) class ≥ II, deep vein thrombosis (DVT), major and minor bleeding and the composite endpoint of major thromboembolic complications including any incidents of EHIT ≥ III, DVT or pulmonary embolism (PE).

View Article and Find Full Text PDF

This study aims to evaluate two of the most commonly used products, the collagen-based patch (Hemopatch) and the micropolysaccharide microspheres powder (Perclot), in the context of stab liver injury in pigs. The objectives of this study were to assess blood loss at various time intervals up to 24 h, survival rates, and mean arterial pressure. The research involved 18 Large-White swine.

View Article and Find Full Text PDF

Objective: CEAP categorizes patients based on disease progression and severity. Whether disease severity is associated with specific patterns of reflux is currently unknown. We hypothesize that patterns of reflux in patients with C2 and C5/6 disease will differ.

View Article and Find Full Text PDF

Objective: The objective of this study is to assess the feasibility of endovascular coiling combined with tissue glue embolism for the treatment of iliac arteriovenous fistula (AVF) secondary to deep vein thrombosis (DVT) of the lower extremities. In addition, we aim to summarize the treatment methods and enhance understanding of the disease.

Methods: This research analyzes the clinical data and medical imaging materials of 20 cases with iliac AVF secondary to lower extremity DVT, ranging from December 2014 to December 2020, at our hospital.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!